Expedition Therapeutics disclosed the Series B in conjunction with dosing the first patient in its global Phase 2 for the DPP1 inhibitor it licensed from Fosun Pharma.
Yi Larson, Expedition Therapeutics CEO
August 5, 2026 08:00 AM EDT
Expedition gets another $115M for its twist on China NewCo model
A US biotech with a slightly different approach to the burgeoning NewCo model has raised another $115 million for its China-sourced COPD drug candidate.
Virtual …
Expedition Therapeutics, which has raised nearly $300 million to date, is studying a drug it believes to have notable advantages…
New York City-based startup Waypoint Bio has raised $20 million in series A financing to test multiple cell therapies in China.
As Legend Biotech became profitable, the company is navigating the next phase of growth for its flagship CAR-T therapy, Carvykti.…
San Diego's cAMPfield Therapeutics raises $180M Series A backed by Novo Holdings, RA Capital and seven other top-tier life…
Full-Life Technologies gets $150M; Quince finds a new life; China biotech gets $50M; SERB Pharmaceuticals buys rights to Hansa…
First payment from US$6 billion deal with Gregory Verdine’s DoveTree swings the Hong Kong-listed firm to a net profit.
